What a Thorough Indication Assessment Actually Requires

Across every role I've held in biotech, one decision has consistently had more impact on a program's trajectory than any other: how thoroughly the team assessed the indication, not just the science, but how the modality, the target, and the treatment context interact.

The pattern I see most often isn't that teams pick bad indications. It's that they evaluate indications from a single angle, usually market size, without assessing how the modality, the target, and the treatment context interact within that indication. A thorough indication assessment forces you to evaluate all of these together. The modality changes which dimensions matter most, but the framework is the same.

Same modality, opposite outcomes. The difference was the assessment.

The first question in any indication assessment is whether the biology of your therapeutic aligns with the pathology of the disease. If it doesn't, nothing else matters. But biological fit alone isn't sufficient. Two AAV gene therapies illustrate this clearly.

Zolgensma, an AAV9 gene therapy for spinal muscular atrophy, was approved in 2019 at $2.1 million per dose. It has generated over $6 billion in cumulative revenue and remains commercially viable. The assessment pointed in the same direction: SMA Type 1 is devastating, with more than 90% of untreated children dying or requiring permanent ventilation by age two. The prior standard of care, Spinraza, required repeated intrathecal injections into the spines of infants every four months, indefinitely. Parents and physicians had a clear reason to choose a one-time intravenous gene therapy.

Roctavian, an AAV5 gene therapy for severe hemophilia A, was approved in 2023 at $2.9 million per dose. In the six months following approval, only one paying patient was treated in the United States. BioMarin tried to find a buyer, couldn't, and voluntarily withdrew the product from the market in early 2026, taking roughly $240 million in losses.

The science behind Roctavian worked, and hemophilia A was not a bad indication. The challenge was that Roctavian struggled to demonstrate clear superiority over a standard of care that was already working well. Most hemophilia A prophylaxis patients were well-managed on Hemlibra, a subcutaneous bispecific antibody administered as infrequently as once monthly. Patient satisfaction was high. Physicians were comfortable with the protocol. Payers understood the cost structure.

Into that environment, Roctavian offered a one-time gene therapy with uncertain long-term durability. Factor VIII levels declined from their initial peak before stabilizing in the mild hemophilia range, and while most patients maintained clinical benefit, the trajectory raised questions about how long the effect would last. At $2.9 million, patients and physicians were being asked to accept meaningful upfront risk over a therapy that was already working well.

These assessments are easier in retrospect than in real time. In 2023, the gene therapy hype cycle made every indication look addressable, and BioMarin had strong clinical data supporting their filing. But the value of a structured indication assessment is that it forces you to ask uncomfortable questions before the market does. Is the unmet need deep enough that patients will switch? Is the existing standard of care good enough that the bar for switching is prohibitively high?

The lesson isn't that gene therapy is a flawed modality. It's that the same modality, targeting a similar biology, at a similar price point, succeeds or fails based on how thoroughly the indication was assessed: the depth of unmet need, the strength of the existing standard of care, and whether the treatment burden is justified by the improvement it delivers. Modality, target, and treatment context all had to be evaluated together.

Headline prevalence is not the same as an addressable market.

Sickle cell disease affects over 100,000 people in the United States. On paper, that's not a small market. But when bluebird bio launched Lyfgenia, a lentiviral gene therapy priced at $3.1 million, only 17 patients had started treatment through the first three quarters. By early 2025, bluebird bio, which at its peak was valued at roughly $9 billion, was sold to private equity for under $30 million.

The prevalence was never the problem. The problem was the gap between headline prevalence and the population that could realistically receive the therapy. Lyfgenia requires myeloablative conditioning, a course of busulfan chemotherapy that destroys the patient's bone marrow before the treated cells can be reinfused. The full treatment journey spans many months. For a patient population that skews young, the near-certain infertility from the conditioning regimen was a major deterrent. In a survey presented at the 2024 American Society of Hematology annual meeting, infertility was cited as a concern by roughly half of sickle cell patients and caregivers considering gene therapy.

On top of the treatment burden, Lyfgenia carried a boxed warning for blood cancer risk. Roughly half of sickle cell patients are on Medicaid, a payer system structured around annual budgets that's fundamentally mismatched to absorbing a $3.1 million one-time cost. And specialized treatment centers were required but many were far from the communities where sickle cell patients actually live.

This wasn't a failure of the science. The biology worked. But the indication assessment stopped at prevalence and unmet need without evaluating how the modality, the target biology, and the treatment context interacted: the conditioning regimen burden for a young population, the safety tolerability threshold, the payer infrastructure, and the geographic accessibility. Together, those dimensions explain why 100,000 patients translated into just 17 treatment starts in the first three quarters on the market.

What it looks like when the full picture aligns.

Dupixent, a monoclonal antibody targeting IL-4 receptor alpha, was approved in 2017 for moderate-to-severe atopic dermatitis. Before Dupixent, there were no approved biologics for the condition. Physicians were relying on off-label immunosuppressants like cyclosporine and methotrexate, drugs with real toxicity that were never designed for atopic dermatitis. The unmet need wasn't theoretical. It was visible in every dermatology clinic.

Rather than treating Dupixent as a skin drug, Sanofi and Regeneron assessed the target biology itself: IL-4 and IL-13 are central drivers of Type 2 inflammation across multiple organ systems, not just the skin. That target assessment, not just the modality choice, is what unlocked the expansion. Dupixent has since been approved in nine indications, including asthma, eosinophilic esophagitis, and COPD, and generated over $14 billion in 2024 revenue.

The lead indication wasn't just a market entry point. It was the starting position for a systematic expansion driven by the biology of the target, not the disease label. Every dimension aligned: deep unmet need, a modality patients could self-administer at home, no approved biologic competitors at launch, and a target biology that opened a path to eight more indications. That's what it looks like when modality, target, and treatment context are assessed together.

What a complete assessment actually requires.

The programs that struggled weren't bad science. They were programs where the indication was evaluated from one or two angles but not the full picture. I've reviewed programs where the team had twenty slides on mechanism of action and target validation but couldn't answer basic questions about the competitive landscape or what physicians would actually need to see to switch. The ones that succeeded were built on a multi-dimensional understanding of how the modality, the target, the disease, and the treatment context intersect.

In my experience, a rigorous indication assessment starts with one pass/fail gate: does the biology of your therapeutic align with the disease pathology? If the modality can't reach the target tissue, or the target isn't validated in the patient population you're pursuing, nothing else matters. If it does, seven additional dimensions determine whether the indication is viable:

1. Depth of unmet need. Not whether the disease is serious, but whether patients and physicians are actively underserved by existing options. Roctavian failed here. Zolgensma succeeded.
2. Treatment burden relative to alternatives. Will patients accept the administration route, dosing frequency, safety profile, and lifestyle impact of your therapy over what they have now? This is where modality and treatment context collide. Lyfgenia required myeloablative conditioning in a young population. That burden was too high relative to the alternatives.
3. Competitive landscape trajectory. Not the landscape today, but where it will be when you reach market. Roctavian entered a market that Hemlibra had already transformed.
4. Real addressable population. Headline prevalence minus every barrier between diagnosis and treatment: payer access, geographic reach, treatment center availability, patient willingness. Lyfgenia's 100,000 patients became 17 starts in three quarters.
5. Capital efficiency to value inflection. How much does it cost to generate the data that moves the program forward, and does the indication allow you to get there with the capital you can realistically raise?
6. Regulatory pathway landscape. Does the indication qualify for expedited pathways, Orphan Drug designation, RMAT, or Breakthrough Therapy? These levers compress timelines and change the capital equation. For rare disease and gene therapy programs in particular, the regulatory landscape can be the difference between a viable path and one that requires twice the runway.
7. Translatability of preclinical models. Do validated animal models exist for this indication, and will results in those models be predictive of clinical outcomes? If the models are weak, you're building your development plan on uncertain ground.

These dimensions have to be evaluated together, not in isolation. A large market with a well-served patient population isn't a good indication just because the revenue opportunity is attractive. A genuine unmet need in a population where treatment burden or payer dynamics limit real-world adoption isn't a good indication either. Every example in this article failed on a dimension that the team underweighted, not one they missed entirely. The modality, the target, and the treatment context shaped which dimensions mattered most in each case.

Getting the external perspective early.

No assessment of modality, target, and treatment context is complete without input from the people who will actually prescribe, receive, and pay for the therapy. Not at Phase 3. At target selection.

This doesn't require a formal advisory board or a six-figure market research engagement. It means reaching out to three to five key opinion leaders in the disease area, ideally before you commit to a disease model, and asking specific questions. Is the current standard of care adequate, or are there patient populations that remain underserved? What would a new therapy need to demonstrate for you to prescribe it over existing options? What administration route and dosing frequency would be realistic? What safety signals would be deal-breakers?

It also means connecting with patient advocacy groups early enough to understand how patients experience their disease and their treatment burden. And having at least one payer-perspective conversation before reimbursement expectations shape your development plan by surprise.

I've seen programs pivot indications after two physician conversations revealed that the competitive landscape was about to shift in ways that weren't visible from the published literature alone. Sometimes the feedback confirms your thesis and gives you confidence to invest. Sometimes it reveals that physicians are satisfied with existing options and wouldn't switch. Both outcomes are valuable. The earlier you learn, the less it costs.

There's a secondary benefit too. When you have direct quotes from physicians and patient advocates describing the unmet need, that becomes part of your investor narrative. It demonstrates that the demand for your therapeutic isn't just an internal assumption. It's been validated by the people closest to the disease.

Indication assessment deserves the same rigor as target validation.

Every biotech team invests significant time and resources validating their therapeutic target. The same rigor should apply to assessing the indication. When companies evaluate indications from a single angle, they create blind spots. A structured assessment that evaluates modality, target, and treatment context together doesn't guarantee success, but it significantly reduces the risk of committing years of work and capital to an indication where the full picture was never examined.

The companies making these decisions right now in obesity, neurodegeneration, and rare disease will be the next set of case studies. Some will be cited as examples of disciplined indication assessment. Others will join the long list of programs where the science was sound but the indication was never fully evaluated. The difference will come down to whether the team assessed modality, target, and treatment context together before committing, or optimized for one dimension and assumed the rest would follow.

That kind of honest assessment is hard to do from inside your own program, and it's even harder under time pressure. Boards want decisions. Investors have timelines. But the best teams I've worked with treat indication assessment the way they treat target validation: as a hypothesis that needs to be tested against every relevant dimension, not confirmed by the ones that look most favorable.

That pressure test is hard to run from inside your own program, which is one of the reasons we built BridgeLine around it.

Sources

1. FDA approves Zolgensma for SMA (May 2019)
2. Novartis FY 2025 Financial Results (Zolgensma cumulative revenue)
3. PMC: Survival analysis of SMA Type 1 (natural history, >90% death or permanent ventilation by age 2)
4. Spinraza HCP: Dosing and administration (intrathecal, every 4 months maintenance)
5. FDA approves Roctavian for hemophilia A (June 2023)
6. BioMarin FY 2023 Results (one US patient treated, $3.5M total Roctavian revenue)
7. BioMarin FY 2025 Results (Roctavian $240M charges)
8. BioMarin voluntary withdrawal of Roctavian (February 2026)
9. Hemlibra prescribing information (dosing regimens)
10. Ozelo et al., NEJM 2022: Valoctocogene roxaparvovec gene therapy for hemophilia A (Factor VIII expression data)
11. FDA approves Lyfgenia for sickle cell disease (December 2023)
12. Lyfgenia prescribing information (busulfan conditioning, boxed warning for hematologic malignancy)
13. STAT News: bluebird bio sold for under $30 million (February 2025)
14. bluebird bio Q3 2024 Results (17 Lyfgenia patient starts through September 2024)
15. ASH 2024: Patient perspectives on gene therapy for sickle cell disease (infertility concerns)
16. NORC: Sickle cell disease prevalence among Medicaid enrollees
17. FDA approves Dupixent for atopic dermatitis (March 2017)
18. Regeneron FY 2024 Results (Dupixent $14.15B revenue)
19. Regeneron: Dupixent approved for ninth indication (AFRS, February 2026)
20. Le Floc'h et al., Allergy 2020: Dual blockade of IL-4 and IL-13 with dupilumab

Timothy S. Luongo, PhD, MSTR

Founder of BridgeLine Translational. BridgeLine provides strategy, intelligence, and resources for biotech, investors, and partners across four services: Competitive Intelligence, Preclinical Strategy, Portfolio Strategy, and Investor/Partner Readiness. Background spans operator roles building IND-enabling programs at Spark Therapeutics (Roche) and StrideBio, and later buy-side evaluation at Sarepta Therapeutics.

Schedule a call